Board Change • Jun 05
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 3 highly experienced directors. Independent Director Henry Cremisi was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Announcement • Jun 04
Daxor Corporation, Annual General Meeting, Jun 23, 2026 Daxor Corporation, Annual General Meeting, Jun 23, 2026. Location: 4 times square, new york 10036, United States Announcement • Mar 27
Daxor Corporation Blood Volume Analysis Metric Validated as Uniquely Accurate Versus Capillary Leak Indexes in New Clinical Data Daxor Corporation announced that new clinical data evaluating the accuracy of capillary leak detection scores compared to BVA was presented at the Society for Critical Care Medicine 2026 Critical Care Congress. The study, titled, 'Mechanistic Specificity of Capillary Leak Indices: Validation in Heart Failure as a Negative Control,' was featured during the Research Snapshot Theater. The research investigated the relationship between traditional clinical scoring methods and direct, in-vivo measurement of albumin escape using Daxor’s Blood Volume Analyzer. Capillary leak occurs when the walls of the blood vessels become permeable, allowing fluid and proteins to escape from the bloodstream into the surrounding tissue (edema). The study utilized Daxor’s BVA system to measure the Albumin Escape Rate—the actual fraction of intravascular albumin leaking across the capillary wall per hour. Researchers compared these direct measurements against four common clinical indices (including the Capillary Leak Index and SOFA score) in a heart failure cohort. Key findings include: The BVA system identified significantly elevated albumin escape rates in patients, even when traditional clinical scores remained 'uniformly low.' Clinical indices showed weak and non-significant correlations with actual albumin escape, suggesting that these common scores may miss significant vascular leakage in the arena of heart failure, considered a non-inflammatory setting. The research confirms that while common clinical scores are designed to detect inflammatory leak (like sepsis), their actual accuracy remains unproven. Daxor’s BVA is the only tool capable of directly measuring albumin leak, including patients with heart failure and sepsis, filling a critical diagnostic gap. Future proposed studies intend to show whether clinical scores are valid in inflammatory leak, or whether in that domain as well, only Daxor’s technology remains the reliable metric of direct measurement of a high albumin leak rate. This data reinforces Daxor’s position as the sole provider of objective, real-time albumin leak rate as well as volume measures. The unique combination of highly accurate and direct volume measurement and leak rate analysis expands the clinical benefit of the test deep into the critical care and heart failure markets, where differentiating the underlying status of a patient's fluid imbalance is essential for proper treatment and precision medicine. 
